148 related articles for article (PubMed ID: 23335436)
1. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors.
Mascarenhas L; Malogolowkin M; Armenian SH; Sposto R; Venkatramani R
Pediatr Blood Cancer; 2013 Jul; 60(7):1103-7. PubMed ID: 23335436
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.
Tran HC; Marachelian A; Venkatramani R; Jubran RF; Mascarenhas L
Pediatr Hematol Oncol; 2015 Feb; 32(1):26-31. PubMed ID: 25551355
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
McGregor LM; Spunt SL; Santana VM; Stewart CF; Ward DA; Watkins A; Laningham FH; Ivy P; Furman WL; Fouladi M
Cancer; 2009 Feb; 115(3):655-64. PubMed ID: 19117350
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
Lam CG; Furman WL; Wang C; Spunt SL; Wu J; Ivy P; Santana VM; McGregor LM
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e13-8. PubMed ID: 24942022
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.
Geoerger B; Doz F; Gentet JC; Mayer M; Landman-Parker J; Pichon F; Chastagner P; Rubie H; Frappaz D; Le Bouil A; Gupta S; Vassal G
J Clin Oncol; 2008 Sep; 26(27):4394-400. PubMed ID: 18802151
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
McGregor LM; Spunt SL; Furman WL; Stewart CF; Schaiquevich P; Krailo MD; Speights R; Ivy P; Adamson PC; Blaney SM
Cancer; 2009 Apr; 115(8):1765-75. PubMed ID: 19170226
[TBL] [Abstract][Full Text] [Related]
9. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Macy ME; Duncan T; Whitlock J; Hunger SP; Boklan J; Narendren A; Herzog C; Arceci RJ; Bagatell R; Trippett T; Christians U; Rolla K; Ivy SP; Gore L;
Pediatr Blood Cancer; 2013 Feb; 60(2):230-6. PubMed ID: 23024067
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
[TBL] [Abstract][Full Text] [Related]
12. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
Geoerger B; Chisholm J; Le Deley MC; Gentet JC; Zwaan CM; Dias N; Jaspan T; Mc Hugh K; Couanet D; Hain S; Devos A; Riccardi R; Cesare C; Boos J; Frappaz D; Leblond P; Aerts I; Vassal G;
Eur J Cancer; 2011 Jan; 47(2):230-8. PubMed ID: 20943374
[TBL] [Abstract][Full Text] [Related]
17. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
20. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
